Angiogenesis is controlled by a balance between pro-and anti-angiogenic 
Introduction
Already two millennia ago, Aristotle described the vital importance of the vascular system as follows: 'the system of blood vessels can be compared with those of watercourses in gardens: they start from one source and branch off into numerous channels, so as to carry a supply to every part of the garden'. After Aristotle, the study of the vascular system, and in particular its growth -a phenomenon generally referred to as angiogenesiscontinued to attract interest from scientists. Yet, it took until 1971, when Judah Folkman proposed that interference with angiogenic factors might impede vessel growth and starve tumours [1] , before interest from the scientific community became fully primed. This led to a tremendous effort on the part Epigenetics Review Series Today, angiogenesis is considered to be a complex and dynamic biological process [2] . A large body of evidence shows that angiogenesis is essential during embryonic development, but becomes notably quiescent in adulthood [3, 4] . Remarkably [2, 5, 6] .
Angiogenesis is genetically pre-determined

As with most biological processes, angiogenesis varies considerably between individuals. Tantalizing examples of how genetic variability contributes to phenotypic variability exist, raising the question whether such genetic variability may also determine the degree of angiogenesis and contribute to disease.
Quantitative genetic analysis of circulating angiogenic factors, including epidermal growth factor (EGF) and angiogenin, has shown that variation in the expression of these molecules can be attributed to genetic effects [7] . For the vascular endothelial growth factor (VEGF), heritability estimates were even responsible for 80% of the genetic variability, whereas environmental factors determined only 20% (ref. [7] ). Similar effects were seen in nuclear families, where significant correlations between VEGF plasma levels were observed in all pairs of relatives, except in spouses [8] 
. This clearly indicates that genetic factors influence the inter-individual variability in angiogenic responsiveness. Understanding the genetic basis of such phenotypic variation is currently one of the major goals and challenges of human genetic studies. Surprisingly, however, relatively few studies designed to dissect the genetic basis of angiogenesis (i.e. the 'angio-genome') have been performed so far.
In a seminal study, Rohan et [9] . The response to Vegf was subsequently mapped to regions on chromosomes 2 and 10, which contained candidate angiogenesisrelated genes including those for endostatin, matrix metalloproteinase 11, integrin-ß2 (ref. [10] ). Because genetic susceptibility may vary according to the angiogenic stimulator, a similar mapping approach to identify loci that influence basic fibroblast growth factor (Fgf-2)-induced neovascularization was undertaken [11] . Four [12] , translocations, copy number variations (CNVs) [13] , epigenetic changes (DNA methylation and histone modifications) [14] and non-coding RNAs (microRNAs) [15] are found to importantly regulate gene expression (Fig. 1) . Each of these modifications has been shown to induce a variety of complex human traits and diversity among diseases, and consequently, may also determine the angiogenic response.
We will now briefly describe the precise nature of these different types of genetic variability and systematically review how they may shape the 'angio-genome', affecting angiogenesis in both health and disease. [17, 18] .
Mutations causing vascular anomalies
Venous anomalies
Venous anomalies present as bluish lesions on skin and mucosa and are referred to as cutaneomucosal venous malformations or VMCMs. They are caused by mutations in the endothelial cell-specific receptor TIE2, which acts as a receptor for the angiopoietins, ANG1 and ANG2. Originally, TIE2 was described as the second member of an orphan receptor tyrosine kinase subfamily expressed predominantly in the embryonic endothelium [19, 20] . Consistent with its expression pattern, disruption of Tie2 function in mice resulted in early embryonic lethality due to vascular abnormalities [21] . Ultrastructurally [24] . Loss of Vegfr-3 also impaired remodelling of the expanding embryonic vasculature [25] , thereby confirming the involvement of Vegfr-2 and -3 in the development of the vascular system. Although these knockout studies clearly highlight the importance of Vegfr-2 and -3 during angiogenesis, conditional knockout studies of these receptors are required to study haemangioma formation in mouse models.
Another intriguing concept is that tissues derived from the same neural crest or mesodermal migrating cells, which therefore share the same metameric origin, are all similarly affected in certain anomalies [26] . This suggests that some developmental [30] , and interactions between pericytes and endothelial cells influence maintenance, maturation and remodelling of blood vessels [31] . [62] . No effects were seen in ovarian cancer [65] . In the 5'-untranslated region (UTR) of the VEGF gene, the Ϫ634CC homozygotes correlated with higher circulating VEGF [66] . In vitro, the Ϫ634C allele also disrupted the 5'UTR RNA structure and increased the expression of a long VEGF isoform (L-VEGF) [60] . In breast cancer, Ϫ634CC carriers exhibited larger tumours and increased histologic grading [67] and in prostate cancer, Ϫ634CC carriers had a higher-grade carcinoma [68] . Other studies reported, however, that the Ϫ634C allele was associated with lower VEGF and prolonged survival in colorectal [63] and non-small-cell lung cancer [69] . No effects were seen on breast [62] , renal cell [61] and ovarian carcinoma [65] . Another SNP that reduces VEGF expression is the ϩ936C/T SNP, located in the 3ЈUTR of the VEGF gene [70, 71] (Table 1 and Fig. 2 ) [75] . Fig. 2 ) [77] . The presence of these variants, especially the P582S variant, was shown to cause a significantly higher transcriptional activity correlating with higher mutant HIF-1␣ protein expression and increased vessel density [77] . The P582S mutant genotype also correlates with accelerated tumour progression in head and neck squamous carcinoma [77] and with more severe ulcerative growth pattern in colorectal cancer [78] or survival in transitional cell cancer of the bladder [79] .
The transforming growth factor-ß in vascular anomalies
Genetic variability in HIF-1␣
Mutations in EGLN1, encoding the PHD2 enzyme, which lead to a marked decrease in enzyme activity and increased HIF-1␣ expression, have been described in patients with familial erythrocytosis. Remarkably, however, patients carrying EGLN1 mutations did not exhibit any obvious angiogenic abnormalities [80] . [83] [87] . [12] [102, 103] . [14] . Several epigenetic defects are known to contribute to disease, such as for instance changes in the localized or global density of DNA methylation. [104] . [105, 106] . [107] , and has now been confirmed in various other cancers, including gastric carcinoma [108] , penile squamous cell carcinoma [109] and neuroblastomas [110] . In addition, THBS-1 hypermethylation was found to be significantly associated with distal location, vascular invasion, distant metastasis and worse prognosis in gastric cancer [111] . In primary colorectal cancers, loss of THBS-1 expression also correlated with impaired TGFß signalling, as indicated by decreased SMAD2 phosphorylation and nuclear localization [112] . Furthermore, methylation-induced silencing of THBS-1 expression reduced the concentration of secreted TGFß, thereby attenuating TGFß signalling [112] . Aberrant methylation of THBS-1 thus represents an epigenetic mechanism for suppressing TGFß signalling in cancer. Extensive hypermethylation of a large CpG island in Sprouty4 has been observed in high-grade prostate cancer, whereas benign prostate hyperplasia tissues were predominantly unmethylated [113] . Furthermore, suppression of Sprouty4 expression correlated with the methylation status of this CpG region in clinical samples [113] . [114] , and of tissue inhibitor of metalloproteinase-2 and -3 (TIMP-2 and -3) in various tumours [106] , have also been observed.
SNPs in VEGFR-
. Although no clinical information about the functional consequences of this functional SNP in the VEGFR-1 promoter is available yet, the intriguing possibility arises that this SNP modulates the heterogeneous P53 response in cancer patients.
Variations in angiogenic genes are linked with neurodegeneration
In the midst of the excitement over the therapeutic effects of neutralizing VEGF in cancer, there emerged, a few years ago, an unexpected discovery -the existence of a novel link between VEGF and neurodegenerative disease. Transgenic mice with a targeted deletion of the hypoxia-responsive element in the Vegf promoter, resulting in reduced Vegf expression, developed adult-onset, progressive motor neurodegeneration, with pathologic features consistent with amyotrophic lateral sclerosis (ALS) [84]. Vegf also exhibited a huge therapeutic potential in animal models for ALS. The connection between Vegf and ALS in rodents was also confirmed in human beings: the low VEGF-producing alleles of the
The discovery of the link between VEGF and ALS has stimulated interest in evaluating the role of other angiogenic factors in ALS. Recently and most surprisingly, mutations in angiogenin (ANG) and progranulin (PGRN) genes were identified in patients with ALS and frontotemporal dementia, respectively. Greenway and colleagues focused their attention on ANG and identified seven different missense mutations in the ANG gene from ALS patients, six of which were in evolutionary conserved regions [88]. Initially, these ANG mutations were only detected in ALS patients who shared a common ancient haplotype from Scottish/Irish ancestry, but more recent findings revealed that a limited number of mutations is also present in ALS patients from other ancestries (e.g. from Hispanic [89] or Italian ancestry [89, 90]). Mutations in PGRN typically cause a form of frontotemporal dementia with ubiquitine-positive tau-negative inclusions [91], but more recent findings indicate that PGRN mutations can be associated with motor neuron degeneration and various clinical subtypes of dementia. PGRN is a pluripotent secreted growth factor that mediates cell cycle progression, stimulates neovascularization and is highly expressed in aggressive cancer cell lines. PGRN also plays a major role in breast tumourigenesis by conferring resistance to tamoxifen [92]. At least part of the angiogenic and tumour-proliferative effects of PGRN and ANG seem to be mediated through VEGF: ANG appears to be a downstream effector of VEGF in endothelial cells [93], whereas PGRN up-regulates expression of VEGF in breast cancer cells. Little is known, however, about the functions of PGRN and ANG in the CNS [94]. One of the outstanding questions yet to be answered is to what degree the angiogenic activity of these molecules might also trigger vascular defects in neurodegenerative disease, thereby contributing to disease development.
Angiogenic factors in genome-wide association studies
The recent unbiased identification of SNPs on a genome-wide level has become a fruitful enterprise in identifying novel genes in complex diseases and numerous SNPs have been unambiguously identified to underlie disease susceptibility
Epigenetic regulation of angiogenesis
In multicellular organisms, the identity of each cell is determined by its unique gene-expression pattern. This identity is remembered and passed on to daughter cells by epigenetic mechanisms, which are heritable changes that do not involve changes in the DNA sequence
In mammals, DNA methylation is confined to the addition of a methyl group to the cytosine in a CpG dinucleotide. This covalent modification is known to have an essential role in genome function and has been implicated in processes such as gene regulation, chromosomal stability and parental imprinting
Aberrant DNA methylation commonly occurs in human cancers in the form of regional hypermethylation and genome-wide hypomethylation: hypermethylation of CpG islands located in the promoter regions of tumour suppressor genes results in transcriptional silencing, whereas global DNA hypomethylation (also known as demethylation) is associated with activation of protooncogenes and generation of genomic instability
Methylation of anti-angiogenic factors
Various examples of aberrant methylation in angiogenic genes exist. Hypermethylation of the thrombospondin 1 (THBS-1) gene, an angiogenesis inhibitor with tumour suppressor properties, was first found in glioblastoma multiforme
Hypermethylation of ADAMTS-8, a secreted protease with antiangiogenic properties, and concomitant down-regulation of ADAMTS-8 expression in brain tumours
Hypermethylation of anti-angiogenic factors in cancer is thus a commonly used mechanism by the tumour to promote a proangiogenic state.
Intriguingly, the opposite situation, whereby the expression of pro-angiogenic genes is stimulated by epigenetic mechanisms, has also been observed. Indeed, overexpression of the lymphangiogenic molecule, VEGF-C, due to demethylation was reported in gastric cancer cell lines [115] . Notably, overexpression of VEGF-C is well known to correlate with lymphatic vessel density and lymph node metastasis [116, 117] . Studies with the rodent carcinogen, phenobarbital, have also shown that methylation patterns are altered to a greater extent in liver tumour-susceptible as compared to resistant mice. Uniquely, some of the hypo-methylated genes in the susceptible mice are involved in angiogenic processes: e.g. chymase 1, tyrosine kinase non-receptor 2 and ephrin B2 [118] .
Methylation as a second hit event in cancer
Mutations in cancer typically consist of a localized intragenic mutation (e.g. point mutation, microdeletion, etc.) followed by a second hit event, frequently being a large deletion or mitotic recombination, and resulting in loss of heterozygosity of the tumour suppressor gene. An equivalent cause of second hit has been recognized by the phenomenon of hypermethylation of tumour-suppressor genes [105] .
A -1) , is down-regulated [125] . An independent study by Mottet et al. found that HDAC7 silencing also leads to an increase in PDGF-B expression, as well as inhibition of endothelial cell migration [126] . Another member of the HDAC gene family, SIRT1, plays a key role in angiogenic signalling: SIRT1 is highly expressed in the vasculature during blood vessel growth, where it controls the angiogenic activity of endothelial cells [127] . Loss of SIRT1 function blocks sprouting angiogenesis and branching morphogenesis of endothelial cells with consequent down-regulation of genes involved in blood vessel development and vascular remodelling [127] [129] . A number of these genes, including clusterin, fibrillin and quiescin Q6 was also down-regulated in human tumour endothelium and functional analysis using RNA interference confirmed that these were negative regulators of endothelial cell growth in a collagen gel assay [129] . This proves that HDAC inhibitors also directly affect endothelial cell biology and angiogenesis. Additional studies have also reported that HDAC inhibitors influence the expression of the angiogenesis-related genes angiopoietin-2, TIE-2, survivin and eNOS [130, 131] , and attenuated VEGF-induced phosphorylation of AKT and ERK1/2 in endothelial cells [132] . Angiopoietin-2, survivin and CXCR4 up-regulation by VEGF in endothelial cells was also inhibited [132] 
Micromanagers of angiogenesis
Over the past few years, microRNAs (miRNAs) have emerged as a prominent class of gene regulators and have been implicated in diverse biological processes [133] [133] . In human beings, miRNA disruption has been described in association with several cancers Ϫ a finding with important implications for cancer aetiology, diagnosis and potentially for cancer treatment [135] .
Evidence 
